Recently the role of its impairment has been investigated among patients carrying KRAS mutations: loss of LKB1 defines a distinct phenotype of NSCLC, characterized by an aggressive behavior and resistance to standard treatment [17]. The gene discussed is STK11; the disease is non-small cell lung carcinoma.